|
Market Closed -
Nasdaq Stockholm
12:00:00 2026-10-16 pm EDT
|
5-day change | 1st Jan Change | ||
| 2.020 SEK | +3.91% |
|
+18.41% | +2.54% |
| Sep. 24 | Irlab appoints Janne Backman as new chairman | FW |
| Sep. 24 | Irlab Therapeutics AB Announces Board Changes, Effective September 25, 2026 | CI |
Company Valuation: IRLAB Therapeutics AB
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,277 | 1,987 | 389 | 557.6 | 167.3 | 300.4 | - |
| Change | - | -12.75% | -80.42% | 43.33% | -69.99% | 79.53% | - |
| Enterprise Value (EV) | 1,875 | 1,734 | 277.7 | 494.2 | 167.3 | 300.4 | 300.4 |
| Change | - | -7.53% | -83.98% | 77.96% | -66.14% | 79.53% | 0% |
| P/E | 44x | -17.5x | -2.19x | -6.72x | - | - | - |
| PBR | - | 6.83x | - | 17.1x | - | - | - |
| PEG | - | 0x | -0x | 0.1x | - | - | - |
| Capitalization / Revenue | 11x | 32.5x | 68.5x | 5.89x | 2.91x | 2.97x | 2.1x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 2.97x | 2.1x |
| EV / EBITDA | 0x | -0x | -0x | -0x | -0x | -10.6x | 7.78x |
| EV / EBIT | 0x | -0x | -0x | -0x | -0x | -9.57x | 8.68x |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | 1 | -2.19 | -3.43 | -1.6 | - | - | - |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | 207.8 | 61.14 | 5.678 | 94.63 | 57.46 | 101.2 | 143.2 |
| EBITDA 1 | 56.05 | -108.3 | -176.4 | -70.53 | -89.08 | -28.4 | 38.6 |
| EBIT 1 | 52.58 | -113.1 | -180.8 | -75.11 | -93.4 | -31.4 | 34.6 |
| Net income 1 | 51.78 | -113.4 | -177.8 | -83.13 | -110 | -36.1 | 34.6 |
| Net Debt | -401.9 | -252.8 | -111.3 | -63.38 | - | - | - |
| Reference price 2 | 44.000 | 38.300 | 7.500 | 10.750 | 1.970 | 2.020 | 2.020 |
| Nbr of stocks (in thousands) | 51,748 | 51,868 | 51,868 | 51,868 | 84,938 | 148,712 | - |
| Announcement Date | 2/23/22 | 2/23/23 | 2/7/24 | 2/12/25 | 2/25/26 | - | - |
1SEK in Million2SEK
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 30.33M | |
| 35.96x | 12.96x | 27.14x | 0.55% | 1,120B | |
| 37.4x | 6.3x | 17.74x | 2.09% | 616B | |
| 36.43x | 8.36x | 17.24x | 2.43% | 504B | |
| 20.46x | 4.99x | 12.38x | 2.64% | 367B | |
| 106.52x | 5.95x | 25.12x | 2.33% | 360B | |
| 21.18x | 5.54x | 13.63x | 2.88% | 288B | |
| 21.7x | 4.38x | 12.55x | 2.01% | 258B | |
| 27.46x | 7.06x | 12.64x | 2.33% | 234B | |
| -45.63x | 6.99x | 27.07x | 2.11% | 194B | |
| Average | 29.05x | 6.95x | 18.39x | 2.15% | 394.09B | |
| Weighted average by Cap. | 34.72x | 8.20x | 20.04x | 1.84% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- IRLAB A Stock
- Valuation IRLAB Therapeutics AB
Select your edition
All financial news and data tailored to specific country editions
